Conversion of AspireAssist System® to Sleeve Gastrectomy: Technical Video Description

  • Ramon VilallongaEmail author
  • Refik Bademci
  • Renato Roriz-Silva
  • Sergi Sanchez-Cordero
  • Yuhamy Curbelo
  • Ariel Almanza
Multimedia Article



The AspireAssist System® (Aspire Bariatrics, Inc. King of Prussia, PA) is a new endoscopic procedure used to treat obese patients. The aim of this dedicated video is to present a case that required revision surgery due to failure of the AspireAssist System®, and to show how the cannula was removed from the abdomen, and why sleeve gastrectomy (SG) was a good option for revisional surgery in that patient. We aim to discuss technical aspects.

Patient and Methods

A 43-year-old female patient who underwent a placement in 2016. Her initial BMI (body mass index) was 38 kg/m2, with a follow-up period of 26 months. A revisional surgery was performed including dissection of the previous gastric fistula and adhesiolysis from the previous AspireAssist System® placement. A complete dissection of the gastrostomy, including removal of all the system, was done. A decision was made, once the incisura angularis and the placement of a 40 Fch bougie showed that the transection could be performed. SG was done. Patients showed an uneventful postoperative course and 4 months follow-up with 45% EWL.


In case of having the device in place, the surgeon must be aware to remove intraoperatively or endoscopically, the device. Surgeons should consider endoscopic removal of the AspireAssist System® before conversion to another procedure (SG or GBP) at least 6 months of the removal.

Removal of the AspireAssist System® should be performed endoscopically but direct conversion to another bariatric procedure can be considered, either to SG or GBP depending on the technical intraoperative aspects.


AspireAssist System® Sleeve gastrectomy Laparoscopic revisional surgery Conversion Weight regain Failure 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Sullivan S. Aspiration therapy for obesity. Gastrointest Endoscopy Clin N Am. 2017;27:277–88.CrossRefGoogle Scholar
  2. 2.
    Nyström M, Machytka E, Norén E, et al. Aspiration therapy as a tool to treat obesity: 1- to 4-year results in a 201-patient multi-center post-market European Registry Study. Obes Surg. 2018;28:1860–8.CrossRefGoogle Scholar
  3. 3.
    Kumar N, Sullivan S, Thompson CC. The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy. Diabetes Metab Syndr Obes. 2017;10:311–6.CrossRefGoogle Scholar
  4. 4.
    Thompson CC, Abu Dayyeh BK, Kushner R, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol. 2017;112:447–57.CrossRefGoogle Scholar
  5. 5.
    Norén E, Forssell H. Aspiration therapy for obesity; a safe and effective treatment. BMC Obes. 2016;28:56.CrossRefGoogle Scholar
  6. 6.
    López-Nava G, Bautista-Castaño I, Jimenez A, et al. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis. 2015;11:861–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.QUIROBES, Integral Obesity CareCentro Médico TeknonBarcelonaSpain
  2. 2.Endocrine, Metabolic and Bariatric Unit, General Surgery DepartmentVall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Center of Excellence for the EAC-BCBarcelonaSpain
  3. 3.Camlica HospitalIstanbul Medipol UniversityIstanbulTurkey
  4. 4.Department of Medicine, Division of General Surgery, Hospital de Base of Porto VelhoFederal University of Rondônia - UnirPorto VelhoBrazil
  5. 5.General Surgery DepartmentConsorci Sanitari de l’AnoiaBarcelonaSpain
  6. 6.General Surgery DepartmentHospital Universitari de Vic (Consorci Hospitalari de Vic)VicSpain

Personalised recommendations